RecallReported October 28, 2026

Class II recall by Pfizer

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, M…

FDA's record ↗

FDA's enforcement report of October 28, 2026 lists a Class II recall by Pfizer of Manhattan, NY. Product: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, M…. Status: Ongoing.

On the record

Recalling firm
Pfizer
Location
Manhattan, NY
Classification
Class II
Status
Ongoing
Recall number
D-0052-2027
Product type
Drugs
Brand names
LEVOXYL
Generic names
LEVOTHYROXINE SODIUM
Recall initiated
2026-09-29
Reported by FDA
2026-10-28
Source
FDA enforcement reports ↗

The full record

An account shows the reason for the recall, where the product was distributed and the lots.

What a recall is

FDA classifies a recall by the hazard. Class I: a reasonable probability that the product will cause serious adverse health consequences or death. Class II: the product may cause temporary or medically reversible harm, or the probability of serious harm is remote. Class III: the product is not likely to cause adverse health consequences.

More

Watch Pfizer

A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.

From FDA enforcement reports. The record may have changed since it was read.

Approve Suite is not affiliated with FDA, or with Pfizer.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.